查詢結果分析
相關文獻
- Perindopril Monotherapy in Systemic Hypertension
- Valsartan Monotherapy in Systemic Hypertension
- AROTINOLOL治療原發性高血壓的臨床研究
- 運動對高血壓的影響
- Unexpected Pheochromocytoma--A Case Report of Anesthesia in a Uremic Patient
- Relationship between Microalbuminuria, Left Ventricular Mass and Function in Essential Hypertension
- The Effect of Sphenopalatine Postganglionic Neurotomy on the Alteration of Local Cerebral Blood Flow of Normotensive and Hypertensive Rats in Acute Cold Stress
- 衛生教育對於榮民之家高血壓老人自我照顧行為與血壓控制之影響
- 長期阻斷內生性一氧化氮對血壓的影響:正常鼠與高血壓鼠間的比較
- Comparison of Clinical Efficacy and Adverse Effects between Extended-release Felodipine and Slow-release Diltiazem in Patients with Isolated Systolic Hypertension
頁籤選單縮合
題 名 | Perindopril Monotherapy in Systemic Hypertension=Perindopril之單一療法對高血壓之療效 |
---|---|
作 者 | 黃耀星; 顏學偉; 林慶正; 李洮俊; | 書刊名 | Acta Cardiologica Sinica |
卷 期 | 14:3 民87.07-09 |
頁 次 | 頁131-137 |
分類號 | 418.221 |
關鍵詞 | 單一療法; 血管增壓轉化酶抑制劑; 攜帶式自動血壓測量儀; 晝夜變動節律; 高血壓; Perindopril; Monotherapy; ACE inhibitor; Ambulatory blood pressure monitoring; Circadian rhythm; Systemic hypertension; |
語 文 | 英文(English) |
中文摘要 | 背景:血管增壓轉化□抑制劑(ACE-1)為高血壓治療劑之一,Perindopril是一種長效型ACE-1,其代謝物Perindoprilat之半衰期約為27-30小時。本研究是以二十四小時血壓監測儀來評估Perindopril到輕中度血壓之降壓療效。本研究共有21例(男12例,女9例)平均年齡為46 ± 10歲。在兩週的安定劑期後,如其門診的水銀舒張壓>95毫米汞柱,而非次發性高血壓時,做第一次二十四小時血壓監測,如二十四小時血壓監測之標準值屬WHO,Stage I-II,則接受約五週的Perindopril治療。而Perindopril的劑量,為每天4至8mg,在上午(8至9點間)服用一次平均使用劑量每天6.8mg。而每個病人在治療前、後各做一次(共兩次)二十四小時之攜帶型自動血壓及心跳監測(機型為Space Labs 90207)。 結果顯示:除了在夜間2 AM、4 AM及6州,血壓下降較少之外,在治療後之24小時平均收縮壓(systolic BP)及舒張壓(diastolic BP)均較治療前之血壓呈有意義之下降,即(p值<0.05/0.05)。而夜間血壓都呈有意義下降並保持有治療前之晝夜變動節律,治療前後之心跳不變。 這些病例在Perindopril治療前後均接受臥、坐、立等姿勢改變之生理測驗。結果顯示治療後之血壓均較治療前呈有意義之下降,而未發現有姿勢性低血壓現象。有4例發生乾咳,但未因此嚴重到須停止使用該抗壓劑。 因此,一天一次Perindopril單一療法,可以提供有效控制血壓達24小時之久,而無顯著之副作用。其有效率約71%。 |
英文摘要 | Background. Perindopril is a new, potent long-acting angiotensin-converting enzyme inhibitor. Its active metabolite, perindoprilat, has a terminal half life of 27 to 30 hours. Theoretically, that makes its sutiable for once-daily treatment of hypertension. This study assessed the 24-hour efficacy and tolerability of perindopril in Chinese patients with mild to moderate hypertension of World Health Organization Stage I to II. Methods. A total of 21 patients ages 33 to 64 years (mean 46±10), entered a 2-week washout period. All patients had ambulatory diastolic blood pressure (BP) > 90 mmHg and were given active treatment with perindopril for 4 to 7 weeks. The dose of perindopril was titrated from 4 to 8 mg daily (at 8 - 9 AM). In each patient, 24 hour ambulatory BP monitoring (Space Labs 90207) was performed twice, once before and once following treatment. Results. Mean 24-hour systolic/diastolic BPs after perindopril were significantly decreased compared to baseline values (132±11/86±6 vs. 146 ±10/96 ± 7 mmHg (P<.05/0.05). The average-dose of perindopril was 6.8 mg daily after a titration period of 5 weeks of treatment. Mean daytime (6 AM to 6 PM) BP decreased from 148±10/96±7 to 134±12/87±7 mmHg (p<0.05/0.05), and night-time BP decreased from 143±14/76±11 to 128±12/74±11 mmHg (p<0.05/0.05). Systolic BP reduction was more pronounced during the day. Before treatment, the circadian variation showed a peak BP at 12 AM and a nadir at 2 AM. After treatment, significant BP reduction (p<0.05/0.05) was seen in 21 of the 24 hour points. The circadian rhythm was preserved. Mean heart rate did not change significantly after treatment. Four patients had a nonproductive cough. Conclusion. Perindopril administered as once-daily monotherapy provided effective BP control over a 24-hour period with preserved circadian rhythm. |
本系統中英文摘要資訊取自各篇刊載內容。